300 related articles for article (PubMed ID: 2797879)
21. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.
Kayser FH; Novak J
Am J Med; 1987 Apr; 82(4A):33-9. PubMed ID: 3555058
[TBL] [Abstract][Full Text] [Related]
22. [Inhibitory and fatal activity of amoxicillin, erythromycin and josamycin against Streptococci].
Savoia D; Angeretti A
G Batteriol Virol Immunol; 1981; 74(7-12):283-96. PubMed ID: 7347699
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.
Dette GA; Knothe H; Koulen G
Drugs Exp Clin Res; 1987; 13(9):567-76. PubMed ID: 2962847
[TBL] [Abstract][Full Text] [Related]
24. [In vitro activity of miocamycin compared with four other macrolides and with pristinamycin against Branhamella catarrhalis].
Suermondt G; Denamur E; Fleuret A; Laurans G; Orfila J
Pathol Biol (Paris); 1989 May; 37(5):386-9. PubMed ID: 2506513
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial properties of erythromycin and colistin impregnated bone cement. An in vitro analysis.
Ruzaimi MY; Shahril Y; Masbah O; Salasawati H
Med J Malaysia; 2006 Feb; 61 Suppl A():21-6. PubMed ID: 17042224
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
Hardy DJ; Hensey DM; Beyer JM; Vojtko C; McDonald EJ; Fernandes PB
Antimicrob Agents Chemother; 1988 Nov; 32(11):1710-9. PubMed ID: 3252753
[TBL] [Abstract][Full Text] [Related]
27. [Susceptibility of potential periodontopathic bacteria to metronidazole, spiramycin and their combination].
Mouton C; Dextraze L; Mayrand D
J Biol Buccale; 1984 Mar; 12(1):17-26. PubMed ID: 6584423
[TBL] [Abstract][Full Text] [Related]
28. [Azithromycin: critical points].
Philippon A; Cluzel R; Soussy CJ
Pathol Biol (Paris); 1995 Jun; 43(6):488-97. PubMed ID: 8539070
[TBL] [Abstract][Full Text] [Related]
29. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial effect of water extract of sumac (Rhus coriaria L.) on the growth of some food borne bacteria including pathogens.
Nasar-Abbas SM; Halkman AK
Int J Food Microbiol; 2004 Dec; 97(1):63-9. PubMed ID: 15527919
[TBL] [Abstract][Full Text] [Related]
31. [In vitro sensitivity of Mycobacterium avium and Mycobacterium xenopi to erythromycin, roxithromycin and doxycycline].
Maugein J; Fourche J; Mormede M; Pellegrin JL
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):565-7. PubMed ID: 2797881
[TBL] [Abstract][Full Text] [Related]
32. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of roxithromycin: a laboratory evaluation.
Chantot JF; Bryskier A; Gasc JC
J Antibiot (Tokyo); 1986 May; 39(5):660-8. PubMed ID: 3733515
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
[TBL] [Abstract][Full Text] [Related]
35. In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains.
Dubreuil L
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():13-9. PubMed ID: 3429381
[TBL] [Abstract][Full Text] [Related]
36. In-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.
Rolston KV; LeBlanc B; Ho DH
J Antimicrob Chemother; 1986 Feb; 17(2):161-3. PubMed ID: 3700283
[TBL] [Abstract][Full Text] [Related]
37. [Bacteriostatic and bactericidal activities of cyclines, macrolides and fluoroquinolones against Chlamydia trachomatis].
Dailloux M; Villemain P
Pathol Biol (Paris); 1992 May; 40(5):455-60. PubMed ID: 1495827
[TBL] [Abstract][Full Text] [Related]
38. Roxithromycin--a new macrolide derivative.
Hejzlar M; Novotný F; Stastná L; Dvorák M; Kittnar E; Sedmidubský V
J Hyg Epidemiol Microbiol Immunol; 1989; 33(4):487-93. PubMed ID: 2696762
[TBL] [Abstract][Full Text] [Related]
39. [Sensitivity of bacteria to antibiotics (Zurich, 2000)].
Zbinden R; Pfyffer GE; Wüst J
Praxis (Bern 1994); 2001 Dec; 90(50):2205-16. PubMed ID: 11793839
[TBL] [Abstract][Full Text] [Related]
40. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
Prado V; Romero J; Herrera N; Marinkovic K; Bustos R
Rev Med Chil; 1993 Oct; 121(10):1128-34. PubMed ID: 8191116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
